Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA:688336)

Market Cap	44.64B
Revenue (ttm)	1.37B
Net Income (ttm)	870.39M
Shares Out	616.79M
EPS (ttm)	1.39
PE Ratio	52.01
Forward PE	145.71
Dividend	0.12 (0.17%)
Ex-Dividend Date	Nov 7, 2025

Volume	10,866,347
Average Volume	10,501,810
Open	72.00
Previous Close	73.00
Day's Range	71.96 - 77.26
52-Week Range	19.82 - 83.00
Beta	0.86
RSI	61.37
Earnings Date	Oct 24, 2025

About SHA:688336

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an injection for anti-human epidermal growth factor receptor-2 treatment; and Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation. The company...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 995
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688336

Financial Performance

In 2024, SHA:688336's revenue was 1.19 billion, an increase of 17.70% compared to the previous year's 1.01 billion. Earnings were 704.58 million, an increase of 139.15%.